$BXP

Kevorkian Eric G sold $12K of BXP

Kevorkian Eric G (SVP, CLO and Secretary) sold 200 shares of BXP, Inc. (BXP) at $60.22 on 2026-05-21.

Original reporting
SEC EDGAR · Kevorkian Eric G
Published May 26, 2026, 3:13 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 26, 2026, 3:16 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$BXP
Neutral
high confidence
Mentioned
$BXP
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BXPNeutralLow
01

Why it matters

Because it lacks any accompanying corporate event (earnings, guidance, M&A, litigation, or regulatory action), the market impact is likely limited to sentiment/positioning signals rather than fundamentals.

02

Market read

Traders may monitor for patterns in insider activity, but this specific transaction is unlikely to be a standalone catalyst.

03

What to watch

Insider sales can be misread without context (diversification, scheduled selling, option exercises/vesting patterns, and prior transaction history).

Relevance 3/10Timing: Immediate (filing date 2026-05-26) but typically limited follow-through.

Background

The article is an SEC Form 4 insider transaction filing for BXP, reporting an officer’s open-market sale.

Company-level read

Ticker impact

$BXPNeutralHigh confidence
Context

BXP disclosed an officer (SVP, CLO and Secretary) open-market sale of 200 shares on 2026-05-21 via SEC Form 4.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to intraday noise around the filing.

Evidence & confidence

The filing is an insider transaction disclosure (Form 4) with no accompanying guidance, deal, or operational update.

Market effects

Minimal; insider sales in REITs generally do not reset sector expectations without additional news.

None indicated.

None indicated.

Counterpoint

The sale may be driven by personal liquidity/tax needs rather than a bearish view, especially with a small dollar amount and no 10b5-1 plan disclosed.

Key entities

  • BXP

    BXP, Inc.; subject of the insider transaction disclosure (officer sale of 200 shares).

  • Kevorkian Eric G

    Officer (SVP, CLO and Secretary) who sold 200 shares of BXP on 2026-05-21.

Related articles

$BXPMed

BXP, Inc. Q2 2026 Earnings Call Summary

Strategic Performance and Market Dynamics BXP delivered a strong second quarter, exceeding FFO guidance by $0.08 and raising the 2026 midpoint by $0.05, driven by faster-than-expected leasing and occupancy gains. Management attributes the leasing momentum to a 'very healthy environment' for premier workplaces, noting that AI is acting as a significant tailwind by driving space expansions and upgrades among tech and professional service firms.

$BXPMed

BXP Secures $1.2B Construction Loan for 343 Madison Avenue Office Tower – Commercial Observer

BXP announced it secured a $1.2B construction loan for its 930,000 sq ft, 46-story office tower at 343 Madison Ave in Midtown, with a four-year term plus a one-year extension option, from Wells Fargo, Bank of America Securities, BNY Mellon and J.P. Morgan. Completion is set for 2029; the project is 50% pre-leased. BXP reported Q2 2026 FFO of $283.4M ($1.78/share) and revenue of $895.7M.

$BXPMed

BXP Selling 7 Times Square Ground Lease

Boston Properties (BXP) is marketing the 7 Times Square ground lease via Eastdil Secured, hiring Will Silverman and Gary Phillips. BXP expects proceeds of $700 million to $750 million, with bids due soon. The 1.2M sq ft tower has a 99-year lease and is 91% occupied. The deal would test Times Square office demand.

$BXPMed

Q3 Financial Results 2025-26

Beximco Pharmaceuticals PLC (AIM: BXP) reported unaudited Q3 and nine-month results ended 31 March 2026. For nine months, net sales rose 13.1% to BDT 41,428.0m (£256.9m) and profit after tax increased 34.0% to BDT 7,048.6m (£43.7m). In Q3, net sales grew 8.1% to BDT 13,627.8m (£84.5m) and PAT rose 30.6% to BDT 2,254.4m (£14.0m).